Knuff & Co LLC Purchases 3,954 Shares of Novo Nordisk A/S (NYSE:NVO)

Knuff & Co LLC lifted its position in Novo Nordisk A/S (NYSE:NVO) by 124.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 7,121 shares of the company’s stock after buying an additional 3,954 shares during the period. Knuff & Co LLC’s holdings in Novo Nordisk A/S were worth $848,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of NVO. International Assets Investment Management LLC raised its stake in Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after buying an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC grew its position in Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after purchasing an additional 1,593,303 shares during the last quarter. Mediolanum International Funds Ltd acquired a new position in Novo Nordisk A/S during the 3rd quarter valued at approximately $98,765,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Novo Nordisk A/S by 10.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 8,589,222 shares of the company’s stock worth $1,102,857,000 after buying an additional 823,036 shares during the last quarter. Finally, Marshall Wace LLP lifted its stake in shares of Novo Nordisk A/S by 34,472.1% during the second quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after buying an additional 689,441 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $99.82 on Tuesday. The company’s 50 day simple moving average is $117.94 and its 200-day simple moving average is $129.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15. The company has a market capitalization of $447.95 billion, a price-to-earnings ratio of 32.30, a price-to-earnings-growth ratio of 1.31 and a beta of 0.42.

Analyst Ratings Changes

A number of equities analysts recently issued reports on NVO shares. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.